Finance

#AI #Chronic pain #Finance #Funding #Start-ups #Stem cells

International start-ups receive funding from BioInnovation 

Three international life sciences start-ups have received investment from the BioInnovation Institute (BII).   The three new ventures were chosen as part of the BII’s focus on developing scientific initiatives across the therapeutics and health tech space.  The companies, Sevenless Therapeutics, VEIL.AI and Myopax, will receive €1.3 million and will form… Read More

#Business & Investment #News

#Business #Finance #Investment

BioXcel Therapeutics raises $260m to support commercial activities

BioXcel Therapeutics has raised $260 million in funding to support the commercial activities of its proprietary, orally dissolving film formulation IGALMI. Previously known as BXCL501, IGALMI is an orally dissolving film formulation of dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder… Read More

#News

#Evotec #Finance #Innovation #Investment #Pharma

Is Toulouse France’s hidden hub of life sciences innovation? 

DDW Deputy Editor Reece Armstrong recently attended the Invest in Toulouse Virtual Round Table to find out how the city is establishing itself as a place of exciting research in the healthcare sectors.   Hosted by Jean-Claude Dardelet, the city’s Deputy Mayor, the roundtable examined how Toulouse is becoming an international… Read More

#Market Reports #News

#Drug development #Finance #Investment

Boyds records growth following investment strategy  

Global drug development consultancy Boyds has reported strong financial growth following a two-year strategy to expand its business.  Boyds saw an increase of over 20% year-on-year in annual revenue in the wake of increased demand for drug development expertise across the UK, US, and Europe. … Read More

#News

#Bone Therapeutics #Finance

Bone Therapeutics hedges bets on cell therapy platform  

Cell therapy company Bone Therapeutics has announced it is shifting its R&D activities towards its most advanced clinical asset, the allogenic cell therapy platform, ALLOB.   The platform    ALLOB is an off-the-shelf allogenic cell therapy platform consisting of human allogeneic bone-forming cells derived from… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Finance #Pharmatech

$100 million invested in AI development

Clinical pharmatech company Exscientia’s Series C financing round was completed with investment of $30 million from BlackRock, which will accelerate its AI drug discovery platform and pipeline. Blackrock funds joined Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital in the investment $100 million round. New capital will be… Read More

#News